+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 58 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the use of PET imaging with the radioligand 18FPI-2620 to detect tau protein buildup in people with Alzheimers disease and control subjects. This open-label, multi-center, pivotal Phase 3 study compares imaging results during life to brain tissue analysis after death to assess the accuracy and safety of this diagnostic method. Participants will receive an intravenous injection of 18FPI-2620 at a dose of 185 MBq 20%. This study is non-randomized and single-group, focusing on the imaging procedure itself without placebo or alternative treatments. The study will continue until autopsy and brain tissue analysis are completed, with an average follow-up period of about one year. During the study, participants will undergo PET scans using 18FPI-2620. Researchers will assess the scans ability to correctly identify tau pathology related to Alzheimers disease by comparing them to post-mortem brain tissue analysis. The study includes safety monitoring and evaluation of the agreement between different readers interpreting the scans. Overall participation lasts until the participants death and brain autopsy, expected on average around one year after the scan.

Age: 50Years +All GendersPhase 3
25 locations
E

Actively Recruiting

Researchers are evaluating BRX011, an oral medication taken once daily, for adults with geographic atrophy secondary to age-related macular degeneration. This phase 12 study aims to assess both the safety and effectiveness of BRX011 compared to a placebo over nearly two years. The study focuses on how well the treatment slows the progression of geographic atrophy. Participants will be randomly assigned to receive either BRX011 capsules or placebo capsules daily. The study lasts 96 weeks and includes multiple visits to monitor health and treatment response. Safety is closely monitored with regular checks including vital signs, lab tests, eye exams, and imaging to detect any adverse effects. During the study, participants will undergo evaluations such as visual acuity testing and imaging of the eye to measure changes in geographic atrophy area. Researchers will track the annual rate of change in the square root of the geographic atrophy area as the primary outcome. Secondary measures include changes in vision under low light and best-corrected visual acuity. Participant well-being is monitored throughout, and the study is sponsored by Biojiva LLC.

Age: 55Years +All GendersPhase 1Phase 2
17 locations
E

Actively Recruiting

Researchers are studying the effectiveness, safety, and tolerability of combining elecoglipron and dapagliflozin compared to using each drug alone in adults with type 2 diabetes mellitus T2DM who are not well controlled by lifestyle changes or other diabetes medications. This phase III trial aims to understand how well these treatments manage blood sugar levels in this population. Participants will be randomly assigned to one of five groups two different doses of elecoglipron combined with dapagliflozin, two doses of elecoglipron combined with a placebo matching dapagliflozin, or dapagliflozin alone with a placebo matching elecoglipron. All medications are taken orally once daily. The study uses a double-blind, parallel-group design to compare these treatments over 40 weeks. During the study, participants will have their blood sugar control measured primarily by changes in Hemoglobin A1c HbA1c from the start to week 40. Secondary measures include body weight changes, fasting plasma glucose, blood pressure, and time to starting rescue medication. Regular assessments will monitor safety and treatment effects throughout the trial period, which lasts about 40 weeks.

Age: 18Years +All GendersPhase 3
303 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the safety, tolerability, and immune response of the BLB-201 vaccine, delivered intranasally, in infants and young children aged 8 months to under 5 years. This Phase 12a randomized, placebo-controlled trial includes participants who may or may not have had prior respiratory syncytial virus RSV infection, aiming to better understand vaccine effects in both RSV seropositive and seronegative groups. Participants receive either one or two doses of BLB-201 at low 106 PFU or high 107 PFU doses or a placebo via the nose on specified days Day 1 and optionally Day 57. Different groups are assigned based on age and RSV antibody status, with doses given intranasally. The study compares these groups to assess safety and immune response at different dose levels and schedules. Throughout the trial, participants undergo monitoring for adverse events within the first month after vaccination. Researchers evaluate solicited adverse events from Day 1 to Day 15 and unsolicited adverse events through Day 29. The study involves medical history reviews, physical exams, laboratory tests, and RSV antibody assays. The trial is expected to continue until late 2028, ensuring thorough safety and immune response assessment over time.

Age: 6Months - 5YearsAll GendersPhase 1Phase 2
18 locations
R

Actively Recruiting

Researchers are evaluating the safety and effectiveness of elismetrep, compared with placebo, for treating moderate to severe migraine in adults. This randomized, double-blind, multicenter outpatient study focuses on patients aged 18 to 75 who experience frequent migraine attacks. The trial aims to better understand elismetreps impact on migraine symptoms and relief. Participants are randomly assigned to receive a single oral dose of either elismetrep 10 mg, elismetrep 20 mg, or placebo. The study is conducted in a parallel design with triple masking to reduce bias. The primary focus is on pain freedom and relief from the most bothersome migraine symptoms within two hours after dosing. During the trial, participants will report their migraine symptoms and responses to treatment using study questionnaires and an electronic diary. Researchers will assess outcomes such as pain relief at 2 hours, sustained pain freedom up to 48 hours, freedom from nausea, photophobia, and phonophobia, and the need for rescue medication. Safety is monitored through adverse event reporting up to 8 days post-dose. The study is expected to last until December 2027.

Age: 18Years - 75YearsAll GendersPhase 3
72 locations
C

Actively Recruiting

Researchers are evaluating two treatment combinations for patients with BRAF-V600 mutant melanoma that has spread to the brain. This phase II trial compares encorafenib, binimetinib, and nivolumab with ipilimumab and nivolumab to see which is more effective in shrinking and controlling brain metastases from melanoma. The study also aims to assess survival, response rates, duration of response, and toxicity of these treatments. Participants are randomly assigned to one of two groups. One group receives encorafenib once daily by mouth, binimetinib twice daily by mouth, and nivolumab intravenously on the first day of each 28-day cycle. The other group receives nivolumab intravenously on day one of all cycles and ipilimumab intravenously over 30 minutes on day one of the first four 21-day cycles, then nivolumab every 28 days. Treatment continues until disease progression or unacceptable side effects. During the study, participants undergo brain and tumor imaging, physical exams, and laboratory tests. After completing treatment, they are followed every six months for two years and then annually up to three years from randomization. Researchers monitor progression-free survival, overall survival, tumor response, brain metastasis response, and safety. Samples of tissue, cerebrospinal fluid, stool, and blood are collected for future research.

Age: 18Years +All GendersPhase 2
331 locations
C

Actively Recruiting

Researchers are studying two surgical procedures to reduce the risk of ovarian cancer in women with BRCA1 genetic mutations. This trial compares bilateral salpingectomy, which removes only the fallopian tubes, with bilateral salpingo-oophorectomy, which removes both fallopian tubes and ovaries. The goal is to find out if removing just the fallopian tubes with delayed ovary removal is nearly as effective as removing both from the start. Participants choose between two groups one undergoes bilateral salpingectomy with the option of later ovary removal, and the other undergoes bilateral salpingo-oophorectomy. Both groups have imaging tests like pelvic ultrasounds or pelvic MRIs during screening and provide blood samples throughout the study. Follow-up visits occur at multiple time points, including 10 to 60 days, 6 months, 12 months, 24 months, and then yearly for up to 20 years. During the study, researchers track if ovarian or related cancers develop and assess symptoms related to estrogen loss, quality of life, cancer-related distress, sexual function, menopausal symptoms, medical decision making, and any adverse events. Various questionnaires and imaging tests support these evaluations. Long-term safety and cancer risk reduction are monitored for up to two decades after surgery.

Age: 35Years - 50YearsFEMALEPhase Not Applicable
574 locations
E

Actively Recruiting

Researchers are evaluating how well the 20-valent pneumococcal conjugate vaccine 20vPnC works against pneumonia caused by seven new types of the Streptococcus pneumoniae bacteria. This study focuses on adults aged 65 years and older who are hospitalized with pneumonia confirmed by chest imaging. The study aims to compare the presence of pneumonia caused by these specific bacteria types in people vaccinated with 20vPnC versus those with pneumonia caused by other bacteria or strains. This observational study involves adults 65 years and older hospitalized with radiologically-confirmed community-acquired pneumonia RADCAP. Participants will provide a urine sample for testing pneumococcal bacteria using BinaxNOW and specific urinary antigen detection assays UAD-1 and UAD-2. Cases are identified by detection of the seven additional bacteria types in 20vPnC beyond the previous 13-valent vaccine, while controls include other pneumonia cases without these serotypes. No treatment is given as part of the study. Participants will be involved for about 1 to 2 days for urine sample collection and providing medical history. Researchers will collect detailed information on illness and hospital stay up to 30 days through medical record review. The main outcome measured is the effectiveness of 20vPnC against pneumonia caused by the seven additional bacterial types over approximately 55 months. Other clinical features and pneumonia types will also be reviewed during this period.

Age: 65Years +All Genders
54 locations
R

Actively Recruiting

Researchers are evaluating whether the drug PF-08046054 works better alone compared to the standard chemotherapy docetaxel in adults with non-small cell lung cancer NSCLC who have tumors expressing PD-L1 at 1% or higher. These participants have cancer that has spread in their body or cannot be removed by surgery or treated with radiation. All participants must have experienced disease progression during or after treatment with PD-L1 or PD-1 inhibitors, platinum-based chemotherapy, and targeted therapies if they have specific genetic mutations. Participants are randomly assigned to one of two groups. One group receives PF-08046054 through an intravenous IV infusion twice every 21-day cycle, while the other group receives docetaxel as an IV infusion once every 21 days. The study may last up to 5 years if the participants cancer responds to treatment. This phase 3 study compares the two therapies to understand their impact on survival and disease progression. During the study, participants will visit the clinic regularly to monitor their health and response to treatment. Researchers will measure overall survival and other outcomes such as progression-free survival, response rates, duration of response, and quality of life using questionnaires. Safety will also be monitored through adverse event evaluations. The study includes biomarker analysis using tumor tissue samples and tracks drug levels and immune responses over time.

Age: 18Years +All GendersPhase 3
447 locations
M

Actively Recruiting

Researchers are conducting a master protocol consisting of three independent, multicenter, randomized, double-blind, placebo-controlled studies to evaluate ACP-204 in adults with Alzheimers Disease Psychosis ADP. The purpose is to assess the efficacy and safety of two doses of ACP-204 compared to placebo. The studies include a Phase 2 dose-response trial followed by two Phase 3 confirmatory trials, each analyzed separately. The research addresses the treatment of psychosis symptoms in adults aged 55 to 95 years with confirmed Alzheimers disease and psychosis. Participants receive either ACP-204 at 30 mg or 60 mg doses or a matching placebo once daily, approximately at the same time each day, with or without food. Each substudy includes a screening period lasting up to 49 days, a 6-week double-blind treatment period, and a 30-day safety follow-up for those not entering an open-label extension. Vital status follow-up is also conducted for participants who end the study early. During the study, participants undergo assessments including the Scale for the Assessment of Positive Symptoms-Hallucinations and Delusions subscales SAPS-HD and the Clinical Global Impression-Severity in the ADP context CGI-S-ADP. Study visits involve evaluation with a designated caregiver or study partner. Safety monitoring and vital status checks continue after treatment, with the total participation duration including screening, treatment, and follow-up periods.

Age: 55Years - 95YearsAll GendersPhase 2Phase 3
154 locations

1-10 of 58

1